This firm's average rating is Buy from 3 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on ProQR Therapeutics market sentiment investors' perception of the future value of ProQR. Let us look at a few aspects of ProQR technical analysis.
Using predictive
technical analysis, we can analyze different prices and returns patterns and
diagnose historical swings to determine the real value of ProQR Therapeutics BV. In general, sophisticated investors focus on analyzing ProQR Therapeutics stock price patterns and their correlations with different microeconomic environment and drivers. They apply predictive analytics to build ProQR Therapeutics's daily price indicators and compare them against related drivers such as
momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional
technical analysis and
fundamental analysis, we attempt to find the most accurate representation of ProQR Therapeutics's intrinsic value. In addition to deriving basic predictive indicators for ProQR Therapeutics, many experienced traders also check how macroeconomic factors affect ProQR Therapeutics price patterns. Please read more on our
technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed
many market ups and downs, anticipate that the market will even out over time. This tendency of ProQR Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as ProQR Therapeutics. Your research has to be compared to or analyzed against ProQR Therapeutics' peers to derive any actionable benefits. When done correctly, ProQR Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in ProQR Therapeutics.
How does ProQR Stands against Peers?
Analyzing ProQR Therapeutics competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to ProQR Therapeutics across multiple sectors and
thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be. Check out
ProQR Therapeutics Competition DetailsProQR Therapeutics Gross Profit
ProQR Therapeutics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing ProQR Therapeutics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show ProQR Therapeutics Gross Profit growth over the last 10 years. Please check ProQR Therapeutics'
gross profit and other
fundamental indicators for more details.
Closer look at ProQR Therapeutics Semi Deviation
ProQR Therapeutics BV has current Semi Deviation of 2.15. Semi-deviation provides a good measure of downside risk for a equity or a portfolio. It is similar to standard deviation, but it only looks at periods where the returns are less than the target or average level.
Semi-deviation is the square root of semi-variance. Semi-variance is calculated by averaging the deviations of returns that have a result that is less than the mean.
Semi Deviation | = | SQRT(SV) |
| = | 2.15 |
Let's now compare ProQR Therapeutics Semi Deviation to its closest peers:
| PRQR | 2.150877034336064 |
| IJR | 1.39 |
| ARWR | 3.59 |
| LYTS | 1.85 |
| IJH | 1.28 |
Our take on today ProQR Therapeutics spike
Sortino ratio is down to 0.61. It may connote a possible volatility fall. ProQR Therapeutics BV is displaying above-average volatility over the selected time horizon. Investors should scrutinize ProQR Therapeutics BV independently to ensure intended market timing strategies are aligned with expectations about ProQR Therapeutics volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure ProQR Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact ProQR Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Our Final Take On ProQR Therapeutics
While other companies within the biotechnology industry are still a little expensive, even after the recent corrections, ProQR Therapeutics may offer a potential longer-term growth to retail investors. The bottom line, as of the 30th of December 2022, our primary 90 days buy-or-sell advice on the enterprise is
Hold. We believe ProQR Therapeutics is
undervalued with
low chance of bankruptcy for the next two years.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Gabriel Shpitalnik is a Member of Macroaxis Editorial Board. Gabriel is a young entrepreneur and writes predominantly on the business, technology, and finance sector. He likes to analyze different equity instruments across a wide range of industries focusing primarily on consumer products and evolving technologies.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of ProQR Therapeutics BV. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com